Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
1.
ACS Chem Neurosci ; 10(8): 3575-3589, 2019 08 21.
Article in English | MEDLINE | ID: mdl-31313908

ABSTRACT

Guanabenz (GBZ), an α2-adrenergic agonist, demonstrated off-target effects that restored protein homeostasis and ameliorated pathobiology in experimental models of neurodegenerative disease. However, GBZ did not directly activate the integrated stress response (ISR), and its proposed mode of action remains controversial. Utilizing an iterative in silico screen of over 10,000 GBZ analogues, we analyzed 432 representative compounds for cytotoxicity in Wild-type, PPP1R15A-/-, and PPP1R15B-/- mouse embryonic fibroblasts. Nine compounds clustering into three functional groups were studied in detail using cell biological and biochemical assays. Our studies demonstrated that PromISR-6 is a potent GBZ analogue that selectively activated ISR, eliciting sustained eIF2α phosphorylation. ISRIB, an ISR inhibitor, counteracted PromISR-6-mediated translational inhibition and reduction in intracellular mutant Huntingtin aggregates. Reduced protein synthesis combined with PromISR-6-stimulated autophagic clearance made PromISR-6 the most efficacious GBZ analogue to reduce Huntingtin aggregates and promote survival in a cellular model of Huntington's disease.


Subject(s)
Adrenergic alpha-2 Receptor Agonists/pharmacology , Cell Survival/drug effects , Guanabenz/analogs & derivatives , Huntington Disease/metabolism , Animals , Eukaryotic Initiation Factor-2/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Mice , Phosphorylation/drug effects , Protein Aggregates/drug effects
2.
Hum Mol Genet ; 28(19): 3175-3187, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31189016

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor nerve cells in the brain and the spinal cord. Etiological mechanisms underlying the disease remain poorly understood; recent studies suggest that deregulation of p25/Cyclin-dependent kinase 5 (Cdk5) activity leads to the hyperphosphorylation of Tau and neurofilament (NF) proteins in ALS transgenic mouse model (SOD1G37R). A Cdk5 involvement in motor neuron degeneration is supported by analysis of three SOD1G37R mouse lines exhibiting perikaryal inclusions of NF proteins and hyperphosphorylation of Tau. Here, we tested the hypothesis that inhibition of Cdk5/p25 hyperactivation in vivo is a neuroprotective factor during ALS pathogenesis by crossing the new transgenic mouse line that overexpresses Cdk5 inhibitory peptide (CIP) in motor neurons with the SOD1G37R, ALS mouse model (TriTg mouse line). The overexpression of CIP in the motor neurons significantly improves motor deficits, extends survival and delays pathology in brain and spinal cord of TriTg mice. In addition, overexpression of CIP in motor neurons significantly delays neuroinflammatory responses in TriTg mouse. Taken together, these data suggest that CIP may serve as a novel therapeutic agent for the treatment of neurodegenerative diseases.


Subject(s)
Amyotrophic Lateral Sclerosis/therapy , Motor Neurons/cytology , Nerve Tissue Proteins/genetics , Peptide Fragments/genetics , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Animals , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Transgenic , Motor Neurons/metabolism , Phenotype , Phosphorylation , Superoxide Dismutase-1/genetics , tau Proteins/metabolism
3.
J Alzheimers Dis ; 60(4): 1429-1442, 2017.
Article in English | MEDLINE | ID: mdl-29036814

ABSTRACT

Several studies have indicated that neuroinflammation is indeed associated with neurodegenerative disease pathology. However, failures of recent clinical trials of anti-inflammatory agents in neurodegenerative disorders have emphasized the need to better understand the complexity of the neuroinflammatory process in order to unravel its link with neurodegeneration. Deregulation of Cyclin-dependent kinase 5 (Cdk5) activity by production of its hyperactivator p25 is involved in the formation of tau and amyloid pathology reminiscent of Alzheimer's disease (AD). Recent studies show an association between p25/Cdk5 hyperactivation and robust neuroinflammation. In addition, we recently reported the novel link between the p25/Cdk5 hyperactivation-induced inflammatory responses and neurodegenerative changes using a transgenic mouse that overexpresses p25 (p25Tg). In this study, we aimed to understand the effects of early intervention with a potent natural anti-inflammatory agent, curcumin, on p25-mediated neuroinflammation and the progression of neurodegeneration in p25Tg mice. The results from this study showed that curcumin effectively counteracted the p25-mediated glial activation and pro-inflammatory chemokines/cytokines production in p25Tg mice. Moreover, this curcumin-mediated suppression of neuroinflammation reduced the progression of p25-induced tau/amyloid pathology and in turn ameliorated the p25-induced cognitive impairments. It is widely acknowledged that to treat AD, one must target the early-stage of pathological changes to protect neurons from irreversible damage. In line with this, our results demonstrated that early intervention of inflammation could reduce the progression of AD-like pathological outcomes. Moreover, our data provide a rationale for the potential use of curcuminoids in the treatment of inflammation associated neurodegenerative diseases.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Inflammatory Agents/pharmacology , Curcumin/pharmacology , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Animals , Astrocytes/drug effects , Astrocytes/metabolism , Astrocytes/pathology , Brain/drug effects , Brain/metabolism , Brain/pathology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Humans , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Inflammation/psychology , Memory Disorders/drug therapy , Memory Disorders/metabolism , Memory Disorders/pathology , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Nerve Degeneration/drug therapy , Nerve Degeneration/metabolism , Nerve Degeneration/pathology , Nerve Degeneration/psychology , Neuroimmunomodulation/drug effects , Neuroimmunomodulation/physiology
4.
J Alzheimers Dis ; 56(1): 335-349, 2017.
Article in English | MEDLINE | ID: mdl-28085018

ABSTRACT

It has been reported that cyclin-dependent kinase 5 (cdk5), a critical neuronal kinase, is hyperactivated in Alzheimer's disease (AD) and may be, in part, responsible for the hallmark pathology of amyloid plaques and neurofibrillary tangles (NFTs). It has been proposed by several laboratories that hyperactive cdk5 results from the overexpression of p25 (a truncated fragment of p35, the normal cdk5 regulator), which, when complexed to cdk5, induces hyperactivity, hyperphosphorylated tau/NFTs, amyloid-ß plaques, and neuronal death. It has previously been shown that intraperitoneal (i.p.) injections of a modified truncated 24-aa peptide (TFP5), derived from the cdk5 activator p35, penetrated the blood-brain barrier and significantly rescued AD-like pathology in 5XFAD model mice. The principal pathology in the 5XFAD mutant, however, is extensive amyloid plaques; hence, as a proof of concept, we believe it is essential to demonstrate the peptide's efficacy in a mouse model expressing high levels of p25, such as the inducible CK-p25Tg model mouse that overexpresses p25 in CamKII positive neurons. Using a modified TFP5 treatment, here we show that peptide i.p. injections in these mice decrease cdk5 hyperactivity, tau, neurofilament-M/H hyperphosphorylation, and restore synaptic function and behavior (i.e., spatial working memory, motor deficit using Rota-rod). It is noteworthy that TFP5 does not inhibit endogenous cdk5/p35 activity, nor other cdks in vivo suggesting it might have no toxic side effects, and may serve as an excellent therapeutic candidate for neurodegenerative disorders expressing abnormally high brain levels of p25 and hyperactive cdk5.


Subject(s)
Alzheimer Disease/drug therapy , Long-Term Potentiation/drug effects , Peptides/pharmacology , Peptides/therapeutic use , Phosphotransferases/metabolism , Alzheimer Disease/complications , Alzheimer Disease/genetics , Animals , Antipsychotic Agents/pharmacology , Antipsychotic Agents/therapeutic use , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Disease Models, Animal , Doxycycline/administration & dosage , Excitatory Amino Acid Agonists/pharmacology , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Female , Hippocampus/drug effects , Hippocampus/physiology , Hyperkinesis/drug therapy , Hyperkinesis/etiology , Long-Term Potentiation/genetics , Male , Maze Learning/drug effects , Mice , Mice, Transgenic , Motor Activity/drug effects , Motor Activity/genetics , N-Methylaspartate/pharmacology , Phosphotransferases/genetics , tau Proteins/metabolism
5.
J Neurosci ; 33(1): 334-43, 2013 Jan 02.
Article in English | MEDLINE | ID: mdl-23283346

ABSTRACT

The aberrant hyperactivation of Cyclin-dependent kinase 5 (Cdk5), by the production of its truncated activator p25, results in the formation of hyperphosphorylated tau, neuroinflammation, amyloid deposition, and neuronal death in vitro and in vivo. Mechanistically, this occurs as a result of a neurotoxic insult that invokes the intracellular elevation of calcium to activate calpain, which cleaves the Cdk5 activator p35 into p25. It has been shown previously that the p25 transgenic mouse as a model to investigate the mechanistic implications of p25 production in the brain, which recapitulates deregulated Cdk5-mediated neuropathological changes, such as hyperphosphorylated tau and neuronal death. To date, strategies to inhibit Cdk5 activity have not been successful in targeting selectively aberrant activity without affecting normal Cdk5 activity. Here we show that the selective inhibition of p25/Cdk5 hyperactivation in vivo, through overexpression of the Cdk5 inhibitory peptide (CIP), rescues against the neurodegenerative pathologies caused by p25/Cdk5 hyperactivation without affecting normal neurodevelopment afforded by normal p35/Cdk5 activity. Tau and amyloid pathologies as well as neuroinflammation are significantly reduced in the CIP-p25 tetra transgenic mice, whereas brain atrophy and subsequent cognitive decline are reversed in these mice. The findings reported here represent an important breakthrough in elucidating approaches to selectively inhibit the p25/Cdk5 hyperactivation as a potential therapeutic target to reduce neurodegeneration.


Subject(s)
Brain/metabolism , Cyclin-Dependent Kinase 5/antagonists & inhibitors , Cyclin-Dependent Kinase Inhibitor Proteins/genetics , Nerve Degeneration/genetics , Neurons/metabolism , Animals , Apoptosis/genetics , Atrophy/genetics , Atrophy/metabolism , Atrophy/pathology , Behavior, Animal/physiology , Brain/pathology , Cyclin-Dependent Kinase 5/genetics , Cyclin-Dependent Kinase 5/metabolism , Cyclin-Dependent Kinase Inhibitor Proteins/metabolism , Memory, Short-Term/physiology , Mice , Mice, Transgenic , Nerve Degeneration/metabolism , Nerve Degeneration/pathology , Neurons/pathology , Phosphorylation , tau Proteins/metabolism
6.
FASEB J ; 27(1): 174-86, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23038754

ABSTRACT

Alzheimer's disease (AD), one of the leading neurodegenerative disorders of older adults, which causes major socioeconomic burdens globally, lacks effective therapeutics without significant side effects. Besides the hallmark pathology of amyloid plaques and neurofibrillary tangles (NFTs), it has been reported that cyclin-dependent kinase 5 (Cdk5), a critical neuronal kinase, is hyperactivated in AD brains and is, in part, responsible for the above pathology. Here we show that a modified truncated 24-aa peptide (TFP5), derived from the Cdk5 activator p35, penetrates the blood-brain barrier after intraperitoneal injections, inhibits abnormal Cdk5 hyperactivity, and significantly rescues AD pathology (up to 70-80%) in 5XFAD AD model mice. The mutant mice, injected with TFP5 exhibit behavioral rescue, whereas no rescue was observed in mutant mice injected with either saline or scrambled peptide. However, TFP5 does not inhibit cell cycle Cdks or normal Cdk5/p35 activity, and thereby has no toxic side effects (even at 200 mg/kg), a common problem in most current therapeutics for AD. In addition, treated mice displayed decreased inflammation, amyloid plaques, NFTs, cell death, and an extended life by 2 mo. These results suggest TFP5 as a potential therapeutic, toxicity-free candidate for AD.


Subject(s)
Alzheimer Disease/prevention & control , Enzyme Activators/pharmacology , Nerve Tissue Proteins/pharmacology , Amino Acid Sequence , Animals , Apoptosis , Mice , Mice, Transgenic , Molecular Sequence Data , Nerve Tissue Proteins/chemistry , Phosphorylation
7.
J Neurosci ; 32(3): 1020-34, 2012 Jan 18.
Article in English | MEDLINE | ID: mdl-22262900

ABSTRACT

The deregulation of cyclin-dependent kinase 5 (Cdk5) by p25 has been shown to contribute to the pathogenesis in a number of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD) and Alzheimer's disease (AD). In particular, p25/Cdk5 has been shown to produce hyperphosphorylated tau, neurofibrillary tangles as well as aberrant amyloid precursor protein processing found in AD. Neuroinflammation has been observed alongside the pathogenic process in these neurodegenerative diseases, however the precise mechanism behind the induction of neuroinflammation and the significance in the AD pathogenesis has not been fully elucidated. In this report, we uncover a novel pathway for p25-induced neuroinflammation where p25 expression induces an early trigger of neuroinflammation in vivo in mice. Lipidomic mass spectrometry, in vitro coculture and conditioned media transfer experiments show that the soluble lipid mediator lysophosphatidylcholine (LPC) is released by p25 overexpressing neurons to initiate astrogliosis, neuroinflammation and subsequent neurodegeneration. Reverse transcriptase PCR and gene silencing experiments show that cytosolic phospholipase 2 (cPLA2) is the key enzyme mediating the p25-induced LPC production and cPLA2 upregulation is critical in triggering the p25-mediated inflammatory and neurodegenerative process. Together, our findings delineate a potential therapeutic target for the reduction of neuroinflammation in neurodegenerative diseases including AD.


Subject(s)
Inflammation/metabolism , Lysophosphatidylcholines/metabolism , Nerve Degeneration/metabolism , Nerve Tissue Proteins/metabolism , Neurons/enzymology , Phospholipases A2, Cytosolic/pharmacology , Age Factors , Amyloid beta-Peptides/metabolism , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Cells, Cultured , Cerebral Cortex/cytology , Chromatography, High Pressure Liquid/methods , Coculture Techniques , Culture Media, Conditioned/pharmacology , Cytokines/metabolism , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Gene Expression Regulation/genetics , Glial Fibrillary Acidic Protein/metabolism , Gliosis/etiology , Gliosis/genetics , Green Fluorescent Proteins/genetics , Humans , In Situ Nick-End Labeling/methods , Inflammation/genetics , Mass Spectrometry/methods , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nerve Degeneration/genetics , Nerve Tissue Proteins/genetics , Neuroglia/physiology , Neurons/drug effects , Peptide Fragments/metabolism , Phospholipases A2, Cytosolic/genetics , Phosphotransferases , RNA, Small Interfering/metabolism , Signal Transduction/genetics , Time Factors , Transduction, Genetic , tau Proteins/metabolism
8.
Sci Rep ; 1: 201, 2011.
Article in English | MEDLINE | ID: mdl-22355716

ABSTRACT

Inflammatory cytokines and endogenous anti-oxidants are variables affecting disease progression in multiple sclerosis (MS). Here we demonstrate the dual capacity of triterpenoids to simultaneously repress production of IL-17 and other pro-inflammatory mediators while exerting neuroprotective effects directly through Nrf2-dependent induction of anti-oxidant genes. Derivatives of the natural triterpene oleanolic acid, namely CDDO-trifluoroethyl-amide (CDDO-TFEA), completely suppressed disease in a murine model of MS, experimental autoimmune encephalomyelitis (EAE), by inhibiting Th1 and Th17 mRNA and cytokine production. Encephalitogenic T cells recovered from treated mice were hypo-responsive to myelin antigen and failed to adoptively transfer the disease. Microarray analyses showed significant suppression of pro-inflammatory transcripts with concomitant induction of anti-inflammatory genes including Ptgds and Hsd11b1. Finally, triterpenoids induced oligodendrocyte maturation in vitro and enhanced myelin repair in an LPC-induced non-inflammatory model of demyelination in vivo. These results demonstrate the unique potential of triterpenoid derivatives for the treatment of neuroinflammatory disorders such as MS.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Interleukin-17 , NF-E2-Related Factor 2 , Triterpenes , Animals , Female , Male , Mice , Rats , Cytokines/metabolism , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/metabolism , Heme Oxygenase (Decyclizing)/metabolism , Heme Oxygenase-1/metabolism , Inflammation , Interleukin-17/metabolism , Membrane Proteins/metabolism , Mice, Inbred BALB C , Mice, Inbred C57BL , Multiple Sclerosis/metabolism , NF-E2-Related Factor 2/metabolism , Nitric Oxide Synthase Type II/metabolism , Oleanolic Acid/analogs & derivatives , Oleanolic Acid/chemistry , Oligodendroglia/cytology , Oligonucleotide Array Sequence Analysis , Rats, Wistar , RNA, Messenger/metabolism , Th1 Cells , Triterpenes/pharmacology
9.
Mol Biol Cell ; 21(20): 3601-14, 2010 Oct 15.
Article in English | MEDLINE | ID: mdl-20810788

ABSTRACT

Cyclin-dependent kinase 5 (Cdk5) plays a key role in the development of the mammalian nervous system; it phosphorylates a number of targeted proteins involved in neuronal migration during development to synaptic activity in the mature nervous system. Its role in the initial stages of neuronal commitment and differentiation of neural stem cells (NSCs), however, is poorly understood. In this study, we show that Cdk5 phosphorylation of p27(Kip1) at Thr187 is crucial to neural differentiation because 1) neurogenesis is specifically suppressed by transfection of p27(Kip1) siRNA into Cdk5(+/+) NSCs; 2) reduced neuronal differentiation in Cdk5(-/-) compared with Cdk5(+/+) NSCs; 3) Cdk5(+/+) NSCs, whose differentiation is inhibited by a nonphosphorylatable mutant, p27/Thr187A, are rescued by cotransfection of a phosphorylation-mimicking mutant, p27/Thr187D; and 4) transfection of mutant p27(Kip1) (p27/187A) into Cdk5(+/+) NSCs inhibits differentiation. These data suggest that Cdk5 regulates the neural differentiation of NSCs by phosphorylation of p27(Kip1) at theThr187 site. Additional experiments exploring the role of Ser10 phosphorylation by Cdk5 suggest that together with Thr187 phosphorylation, Ser10 phosphorylation by Cdk5 promotes neurite outgrowth as neurons differentiate. Cdk5 phosphorylation of p27(Kip1), a modular molecule, may regulate the progress of neuronal differentiation from cell cycle arrest through differentiation, neurite outgrowth, and migration.


Subject(s)
Cell Differentiation , Cyclin-Dependent Kinase 5/metabolism , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Neural Stem Cells/cytology , Neural Stem Cells/enzymology , Phosphothreonine/metabolism , Amino Acid Sequence , Animals , Apoptosis , Cell Proliferation , Cyclin-Dependent Kinase 5/deficiency , Cyclin-Dependent Kinase Inhibitor p27/chemistry , Mice , Molecular Sequence Data , Mutation/genetics , Neurites/metabolism , Neurogenesis , Phosphorylation , Phosphoserine/metabolism , Protein Transport , RNA, Small Interfering/metabolism , Substrate Specificity , Transfection
10.
J Biol Chem ; 285(44): 34202-12, 2010 Oct 29.
Article in English | MEDLINE | ID: mdl-20720012

ABSTRACT

The activity of Cdk5-p35 is tightly regulated in the developing and mature nervous system. Stress-induced cleavage of the activator p35 to p25 and a p10 N-terminal domain induces deregulated Cdk5 hyperactivity and perikaryal aggregations of hyperphosphorylated Tau and neurofilaments, pathogenic hallmarks in neurodegenerative diseases, such as Alzheimer disease and amyotrophic lateral sclerosis, respectively. Previously, we identified a 125-residue truncated fragment of p35 called CIP that effectively and specifically inhibited Cdk5-p25 activity and Tau hyperphosphorylation induced by Aß peptides in vitro, in HEK293 cells, and in neuronal cells. Although these results offer a possible therapeutic approach to those neurodegenerative diseases assumed to derive from Cdk5-p25 hyperactivity and/or Aß induced pathology, CIP is too large for successful therapeutic regimens. To identify a smaller, more effective peptide, in this study we prepared a 24-residue peptide, p5, spanning CIP residues Lys(245)-Ala(277). p5 more effectively inhibited Cdk5-p25 activity than did CIP in vitro. In neuron cells, p5 inhibited deregulated Cdk5-p25 activity but had no effect on the activity of endogenous Cdk5-p35 or on any related endogenous cyclin-dependent kinases in HEK293 cells. Specificity of p5 inhibition in cortical neurons may depend on the p10 domain in p35, which is absent in p25. Furthermore, we have demonstrated that p5 reduced Aß(1-42)-induced Tau hyperphosphorylation and apoptosis in cortical neurons. These results suggest that p5 peptide may be a unique and useful candidate for therapeutic studies of certain neurodegenerative diseases.


Subject(s)
Adaptor Proteins, Signal Transducing/chemistry , Cell Cycle Proteins/chemistry , Cyclin-Dependent Kinase 5/chemistry , Nerve Tissue Proteins/chemistry , Peptide Fragments/chemistry , Phosphotransferases/chemistry , tau Proteins/chemistry , Animals , Apoptosis , Humans , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Peptide Fragments/metabolism , Phosphorylation , Protein Structure, Tertiary , Rats , Tubulin/chemistry
11.
J Neurosci ; 30(25): 8457-67, 2010 Jun 23.
Article in English | MEDLINE | ID: mdl-20573893

ABSTRACT

Cyclin-dependent kinase 5 (Cdk5)-mediated phosphorylation plays an important role in proper synaptic function and transmission. Loss of Cdk5 activity results in abnormal development of the nervous system accompanied by massive disruptions in cortical migration and lamination, therefore impacting synaptic activity. The Cdk5 activator p35 associates with delta-catenin, the synaptic adherens junction protein that serves as part of the anchorage complex of AMPA receptor at the postsynaptic membrane. However, the implications of Cdk5-mediated phosphorylation of delta-catenin have not been fully elucidated. Here we show that Cdk5-mediated phosphorylation of delta-catenin regulates its subcellular localization accompanied by changes in dendritic morphogenesis and synaptic activity. We identified two Cdk5 phosphorylation sites in mouse delta-catenin, serines 300 and 357, and report that loss of Cdk5 phosphorylation of delta-catenin increased its localization to the membrane. Furthermore, mutations of the serines 300 and 357 to alanines to mimic nonphosphorylated delta-catenin resulted in increased dendritic protrusions accompanied by increased AMPA receptor subunit GluR2 localization at the membrane. Consistent with these observations, loss of Cdk5 phosphorylation of delta-catenin increased the AMPA/NMDA ratio. This study reveals how Cdk5 phosphorylation of the synaptic mediator protein delta-catenin can alter its localization at the synapse to impact neuronal synaptic activity.


Subject(s)
Catenins/metabolism , Cyclin-Dependent Kinase 5/metabolism , Neurons/metabolism , Receptors, AMPA/metabolism , Synapses/metabolism , Synaptic Transmission/physiology , Animals , Cells, Cultured , Cerebral Cortex/metabolism , Electrophysiology , Immunohistochemistry , Mice , Mutation , Nerve Tissue Proteins/metabolism , Neurons/cytology , Phosphorylation , Radioligand Assay , Delta Catenin
12.
PLoS One ; 3(8): e2933, 2008 Aug 13.
Article in English | MEDLINE | ID: mdl-18716682

ABSTRACT

BACKGROUND: The uptake and intracellular trafficking of sphingolipids, which self-associate into plasma membrane microdomains, is associated with many pathological conditions, including viral and toxin infection, lipid storage disease, and neurodegenerative disease. However, the means available to label the trafficking pathways of sphingolipids in live cells are extremely limited. In order to address this problem, we have developed an exogenous, non-toxic probe consisting of a 25-amino acid sphingolipid binding domain, the SBD, derived from the amyloid peptide Abeta, and conjugated by a neutral linker with an organic fluorophore. The current work presents the characterization of the sphingolipid binding and live cell trafficking of this novel probe, the SBD peptide. SBD was the name given to a motif originally recognized by Fantini et al in a number of glycolipid-associated proteins, and was proposed to interact with sphingolipids in membrane microdomains. METHODOLOGY/PRINCIPAL FINDINGS: In accordance with Fantini's model, optimal SBD binding to membranes depends on the presence of sphingolipids and cholesterol. In synthetic membrane binding assays, SBD interacts preferentially with raft-like lipid mixtures containing sphingomyelin, cholesterol, and complex gangliosides in a pH-dependent manner, but is less glycolipid-specific than Cholera toxin B (CtxB). Using quantitative time-course colocalization in live cells, we show that the uptake and intracellular trafficking route of SBD is unlike that of either the non-raft marker Transferrin or the raft markers CtxB and Flotillin2-GFP. However, SBD traverses an endolysosomal route that partially intersects with raft-associated pathways, with a major portion being diverted at a late time point to rab11-positive recycling endosomes. Trafficking of SBD to acidified compartments is strongly disrupted by cholesterol perturbations, consistent with the regulation of sphingolipid trafficking by cholesterol. CONCLUSIONS/SIGNIFICANCE: The current work presents the characterization and trafficking behavior of a novel sphingolipid-binding fluorescent probe, the SBD peptide. We show that SBD binding to membranes is dependent on the presence of cholesterol, sphingomyelin, and complex glycolipids. In addition, SBD targeting through the endolysosomal pathway in neurons is highly sensitive to cholesterol perturbations, making it a potentially useful tool for the analysis of sphingolipid trafficking in disease models that involve changes in cholesterol metabolism and storage.


Subject(s)
Glycolipids/metabolism , Glycopeptides/metabolism , Amino Acid Sequence , Cholera Toxin/chemistry , Cholera Toxin/pharmacology , Endosomes/metabolism , Fluorescent Dyes , Gangliosides/metabolism , Genes, Reporter , Glycopeptides/chemistry , Hydrogen-Ion Concentration , Kinetics , Liposomes , Molecular Sequence Data , Sphingolipids/metabolism , Transferrin/metabolism
13.
J Biol Chem ; 283(39): 26737-47, 2008 Sep 26.
Article in English | MEDLINE | ID: mdl-18635547

ABSTRACT

Aberrant phosphorylation of neuronal cytoskeletal proteins is a key pathological event in neurodegenerative disorders such as Alzheimer disease (AD) and amyotrophic lateral sclerosis, but the underlying mechanisms are still unclear. Previous studies have shown that Pin1, a peptidylprolyl cis/trans-isomerase, may be actively involved in the regulation of Tau hyperphosphorylation in AD. Here, we show that Pin1 modulates oxidative stress-induced NF-H phosphorylation. In an in vitro kinase assay, the addition of Pin1 substantially increased phosphorylation of NF-H KSP repeats by proline-directed kinases, Erk1/2, Cdk5/p35, and JNK3 in a concentration-dependent manner. In vivo, dominant-negative (DN) Pin1 and Pin1 small interfering RNA inhibited epidermal growth factor-induced NF-H phosphorylation. Because oxidative stress plays an important role in the pathogenesis of neurodegenerative diseases, we studied the role of Pin1 in stressed cortical neurons and HEK293 cells. Both hydrogen peroxide (H(2)O(2)) and heat stresses induce phosphorylation of NF-H in transfected HEK293 cells and primary cortical cultures. Knockdown of Pin1 by transfected Pin1 short interference RNA and DN-Pin1 rescues the effect of stress-induced NF-H phosphorylation. The H(2)O(2) and heat shock induced perikaryal phospho-NF-H accumulations, and neuronal apoptosis was rescued by inhibition of Pin1 in cortical neurons. JNK3, a brain-specific JNK isoform, is activated under oxidative and heat stresses, and inhibition of Pin1 by Pin1 short interference RNA and DN-Pin1 inhibits this pathway. These results implicate Pin1 as a possible modulator of stress-induced NF-H phosphorylation as seen in neurodegenerative disorders like AD and amyotrophic lateral sclerosis. Thus, Pin1 may be a potential therapeutic target for these diseases.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Cerebral Cortex/metabolism , Heat-Shock Response , Neurofilament Proteins/metabolism , Neurons/metabolism , Oxidative Stress , Peptidylprolyl Isomerase/metabolism , Adaptor Proteins, Signal Transducing/antagonists & inhibitors , Adaptor Proteins, Signal Transducing/genetics , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Alzheimer Disease/therapy , Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Amyotrophic Lateral Sclerosis/therapy , Animals , Apoptosis/drug effects , Apoptosis/genetics , Cell Line , Cerebral Cortex/embryology , Heat-Shock Response/drug effects , Heat-Shock Response/genetics , Humans , Hydrogen Peroxide/pharmacology , NIMA-Interacting Peptidylprolyl Isomerase , Neurofilament Proteins/antagonists & inhibitors , Neurofilament Proteins/genetics , Oxidants/pharmacology , Oxidative Stress/drug effects , Oxidative Stress/genetics , Peptidylprolyl Isomerase/antagonists & inhibitors , Peptidylprolyl Isomerase/genetics , Phosphorylation/drug effects , Protein Kinases/genetics , Protein Kinases/metabolism , Rats , Rats, Wistar , tau Proteins/genetics , tau Proteins/metabolism
14.
J Neurosci ; 28(14): 3631-43, 2008 Apr 02.
Article in English | MEDLINE | ID: mdl-18385322

ABSTRACT

Cyclin-dependent kinase 5 (Cdk5) is predominantly expressed in the nervous system, where it is involved in neuronal migration, synaptic transmission, and survival. The role of Cdk5 in synaptic transmission is mediated by regulating the cellular functions of presynaptic proteins such as synapsin, Munc18, and dynamin 1. Its multifunctional role at the synapse is complex and probably involves other novel substrates. To explore this possibility, we used a yeast two-hybrid screen of a human cDNA library with p35 as bait and isolated human septin 5 (SEPT5), known also as hCDCrel-1, as an interacting clone. Here we report that p35 associates with SEPT5 in GST (glutathione S-transferase)-pull-down and coimmunoprecipitation assays. We confirmed that Cdk5/p35 phosphorylates SEPT5 in vitro and in vivo and identified S327 of SEPT5 as a major phosphorylation site. A serine (S)-to-alanine (A) 327 mutant of SEPT5 bound syntaxin more efficiently than SEPT5 wild type. Additionally, coimmunoprecipitation from synaptic vesicle fractions and Cdk5 wild-type and knock-out lysates showed that phosphorylation of septin 5 by Cdk5/p35 decreases its binding to syntaxin-1. Moreover, mutant nonphosphorylated SEPT5 potentiated regulated exocytosis more than the wild type when each was expressed in PC12 cells. These data suggest that Cdk5 phosphorylation of human septin SEPT5 at S327 plays a role in modulating exocytotic secretion.


Subject(s)
Cell Cycle Proteins/metabolism , Cyclin-Dependent Kinase 5/physiology , Exocytosis/physiology , Neurons/physiology , Animals , Binding Sites/physiology , Brain/cytology , Brain/metabolism , Cells, Cultured , Cricetinae , Cricetulus , Embryo, Mammalian , Growth Hormone/metabolism , Humans , Immunoprecipitation/methods , Mutation/physiology , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Phosphorylation , Protein Binding , Protein Structure, Tertiary/physiology , RNA, Small Interfering/metabolism , Rats , SNARE Proteins/metabolism , Septins , Serine/metabolism , Synaptic Vesicles/metabolism , Syntaxin 1/metabolism , Transfection/methods
15.
Mol Biol Cell ; 18(9): 3645-55, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17626162

ABSTRACT

Under normal conditions, the proline-directed serine/threonine residues of neurofilament tail-domain repeats are exclusively phosphorylated in axons. In pathological conditions such as amyotrophic lateral sclerosis (ALS), motor neurons contain abnormal perikaryal accumulations of phosphorylated neurofilament proteins. The precise mechanisms for this compartment-specific phosphorylation of neurofilaments are not completely understood. Although localization of kinases and phosphatases is certainly implicated, another possibility involves Pin1 modulation of phosphorylation of the proline-directed serine/threonine residues. Pin1, a prolyl isomerase, selectively binds to phosphorylated proline-directed serine/threonine residues in target proteins and isomerizes cis isomers to more stable trans configurations. In this study we show that Pin1 associates with phosphorylated neurofilament-H (p-NF-H) in neurons and is colocalized in ALS-affected spinal cord neuronal inclusions. To mimic the pathology of neurodegeneration, we studied glutamate-stressed neurons that displayed increased p-NF-H in perikaryal accumulations that colocalized with Pin1 and led to cell death. Both effects were reduced upon inhibition of Pin1 activity by the use of an inhibitor juglone and down-regulating Pin1 levels through the use of Pin1 small interfering RNA. Thus, isomerization of lys-ser-pro repeat residues that are abundant in NF-H tail domains by Pin1 can regulate NF-H phosphorylation, which suggests that Pin1 inhibition may be an attractive therapeutic target to reduce pathological accumulations of p-NF-H.


Subject(s)
Cell Nucleus/metabolism , Glutamic Acid/toxicity , Neurofilament Proteins/metabolism , Neurons/drug effects , Neurons/enzymology , Peptidylprolyl Isomerase/antagonists & inhibitors , Alzheimer Disease/enzymology , Alzheimer Disease/pathology , Amyotrophic Lateral Sclerosis/enzymology , Amyotrophic Lateral Sclerosis/pathology , Animals , Apoptosis/drug effects , Cell Nucleus/drug effects , Ganglia, Spinal/cytology , Ganglia, Spinal/enzymology , Genes, Dominant , Humans , Models, Biological , NIMA-Interacting Peptidylprolyl Isomerase , Naphthoquinones/pharmacology , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Structure, Quaternary , Protein Transport/drug effects , RNA, Small Interfering/metabolism , Rats , Spinal Cord/drug effects , Spinal Cord/pathology , Transfection
16.
Biotechnol J ; 2(8): 978-87, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17526058

ABSTRACT

Normal Cdk5 activity, conferred mainly by association with its primary activator p35, is critical for normal function of the cell and must be tightly regulated. During neurotoxicity, p35 is cleaved to form p25, which becomes a potent and mislocalized hyperactivator of Cdk5, resulting in a deregulation of Cdk5 activity. p25 levels have been found to be elevated in Alzheimer's disease (AD) brain and overexpression of p25 in a transgenic mouse results in the formation of phosphorylated tau, neurofibrillary tangles and cognitive deficits that are pathological hallmarks of AD. p25/Cdk5 also hyperphosphorylates neurofilament proteins that constitute pathological hallmarks found in Parkinson's disease and amyotrophic lateral sclerosis. The selective targeting of p25/Cdk5 activity without affecting p35/Cdk5 activity has been unsuccessful. In this review we detail our recent studies of selective p25/Cdk5 inhibition without affecting p35/Cdk5 or mitotic Cdk activities. We found that a further truncation of p25 to yield a Cdk5 inhibitory peptide (CIP) can specifically inhibit p25/Cdk5 activity in transfected HEK cells and primary cortical neurons. CIP was able to reduce tau hyperphosphorylation and neuronal death induced caused by p25/Cdk5 and further studies with CIP may develop a specific Cdk5 inhibition strategy in the treatment of neurodegeneration.


Subject(s)
Brain/enzymology , Cyclin-Dependent Kinase 5/metabolism , Nerve Tissue Proteins/metabolism , Neurodegenerative Diseases/enzymology , Peptides/metabolism , Animals , Enzyme Activation , Humans
17.
Mol Endocrinol ; 21(7): 1552-68, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17440046

ABSTRACT

Glucocorticoids, major end effectors of the stress response, play an essential role in the homeostasis of the central nervous system and influence diverse functions of neuronal cells. We found that cyclin-dependent kinase 5 (CDK5), which plays important roles in the morphogenesis and functions of the nervous system and whose aberrant activation is associated with development of neurodegenerative disorders, interacted with the ligand-binding domain of the glucocorticoid receptor (GR) through its activator p35 or its active proteolytic fragment p25. CDK5 phosphorylated GR at multiple serines, including Ser203 and Ser211 of its N-terminal domain, and suppressed the transcriptional activity of this receptor on glucocorticoid-responsive promoters by attenuating attraction of transcriptional cofactors to DNA. In microarray analyses using rat cortical neuronal cells, the CDK5 inhibitor roscovitine differentially regulated the transcriptional activity of the GR on more than 90% of the endogenous glucocorticoid-responsive genes tested. Thus, CDK5 exerts some of its biological activities in neuronal cells through the GR, dynamically modulating GR transcriptional activity in a target promoter-dependent fashion.


Subject(s)
Cyclin-Dependent Kinase 5/metabolism , Receptors, Glucocorticoid/metabolism , Animals , Base Sequence , COS Cells , Cell Line , Chlorocebus aethiops , Cyclin-Dependent Kinase 5/chemistry , Cyclin-Dependent Kinase 5/drug effects , Cyclin-Dependent Kinase 5/genetics , DNA Primers/genetics , Dexamethasone/pharmacology , Humans , In Vitro Techniques , Ligands , Multiprotein Complexes , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/metabolism , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Protein Structure, Tertiary , Purines/pharmacology , Rats , Receptors, Glucocorticoid/chemistry , Receptors, Glucocorticoid/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Roscovitine , Serine/chemistry , Stress, Physiological/genetics , Stress, Physiological/metabolism , Transcription, Genetic , Two-Hybrid System Techniques
18.
Proc Natl Acad Sci U S A ; 104(2): 660-5, 2007 Jan 09.
Article in English | MEDLINE | ID: mdl-17194758

ABSTRACT

Transient receptor potential vanilloid 1 (TRPV1), a ligand-gated cation channel highly expressed in small-diameter sensory neurons, is activated by heat, protons, and capsaicin. The phosphorylation of TRPV1 provides a versatile regulation of intracellular calcium levels and is critical for TRPV1 function in responding to a pain stimulus. We have previously reported that cyclin-dependent kinase 5 (Cdk5) activity regulates nociceptive signaling. In this article we report that the Cdk5-mediated phosphorylation of TRPV1 at threonine-407 can modulate agonist-induced calcium influx. Inhibition of Cdk5 activity in cultured dorsal root ganglia neurons resulted in a significant reduction of TRPV1-mediated calcium influx, and this effect could be reversed by restoring Cdk5 activity. Primary nociceptor-specific Cdk5 conditional-knockout mice showed reduced TRPV1 phosphorylation, resulting in significant hypoalgesia. Thus, the present study indicates that Cdk5-mediated TRPV1 phosphorylation is important in the regulation of pain signaling.


Subject(s)
Cyclin-Dependent Kinase 5/metabolism , Nociceptors/metabolism , TRPV Cation Channels/metabolism , Amino Acid Sequence , Animals , Base Sequence , Binding Sites , Calcium Signaling , Cyclin-Dependent Kinase 5/deficiency , Cyclin-Dependent Kinase 5/genetics , DNA Primers/genetics , Ganglia, Spinal/metabolism , Mice , Mice, Knockout , Models, Molecular , Molecular Sequence Data , Phosphorylation , Rats , Sequence Homology, Amino Acid , Signal Transduction , TRPV Cation Channels/chemistry , TRPV Cation Channels/genetics , Threonine/chemistry
19.
Mol Biol Cell ; 18(2): 404-13, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17108320

ABSTRACT

Cdk5, a cyclin-dependent kinase, is critical for neuronal development, neuronal migration, cortical lamination, and survival. Its survival role is based, in part, on "cross-talk" interactions with apoptotic and survival signaling pathways. Previously, we showed that Cdk5 phosphorylation of mitogen-activated protein kinase kinase (MEK)1 inhibits transient activation induced by nerve growth factor (NGF) in PC12 cells. To further explore the nature of this inhibition, we studied the kinetics of NGF activation of extracellular signal-regulated kinase (Erk)1/2 in cortical neurons with or without roscovitine, an inhibitor of Cdk5. NGF alone induced an Erk1/2-transient activation that peaked in 15 min and declined rapidly to baseline. Roscovitine, alone or with NGF, reached peak Erk1/2 activation in 30 min that was sustained for 48 h. Moreover, the sustained Erk1/2 activation induced apoptosis in cortical neurons. Significantly, pharmacological application of the MEK1 inhibitor PD98095 to roscovitine-treated cortical neurons prevented apoptosis. These results were also confirmed by knocking down Cdk5 activity in cortical neurons with Cdk5 small interference RNA. Apoptosis was correlated with a significant shift of phosphorylated tau and neurofilaments from axons to neuronal cell bodies. These results suggest that survival of cortical neurons is also dependent on tight Cdk5 modulation of the mitogen-activated protein kinase signaling pathway.


Subject(s)
Apoptosis , Cyclin-Dependent Kinase 5/metabolism , Mitogen-Activated Protein Kinases/metabolism , Neurons/physiology , Animals , Cell Survival/drug effects , Cerebral Cortex/cytology , Cerebral Cortex/enzymology , Cyclin-Dependent Kinase 5/antagonists & inhibitors , Cyclin-Dependent Kinase 5/genetics , Cytoskeletal Proteins/metabolism , MAP Kinase Kinase 1/antagonists & inhibitors , MAP Kinase Kinase 1/metabolism , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/metabolism , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Neurons/drug effects , Neurons/enzymology , PC12 Cells , Phosphorylation , Purines/pharmacology , RNA, Small Interfering/pharmacology , Rats , Roscovitine , Signal Transduction
20.
Neurosignals ; 15(4): 157-73, 2006.
Article in English | MEDLINE | ID: mdl-16921254

ABSTRACT

RasGRF1 is a member of the Ras guanine nucleotide exchange factor (RasGEF) family of proteins which are directly responsible for the activation of Ras and Rac GTPases. Originally identified as a phosphoprotein, RasGRF1 has been shown to be phosphorylated by protein kinase A and more recently, by the non-receptor tyrosine kinases Ack1 and Src. In this report we show that RasGRF1 interacts with and is phosphorylated by Cdk5 on serine 731 to regulate its steady state levels in mammalian cells as well as in neurons. Phosphorylation on this site by Cdk5 leads to RasGRF1 degradation through a calpain-dependent mechanism. Additionally, cortical neurons from Cdk5 knockout mice have higher levels of RasGRF1 which are reduced when wild-type Cdk5 is transfected into these neurons. In mitotic cells, nuclei become disorganized when RasGRF1 is overexpressed and this is rescued when RasGRF1 is co-expressed with active Cdk5. When RasGRF1 levels are elevated in neurons through overexpression of either the wild-type RasGRF1, or the phosphorylation mutant of RasGRF1 and by the transfection of a dominant negative Cdk5 construct, nuclei appeared condensed and fragmented. On the other hand, a reduction of RasGRF1 levels through p35/Cdk5 overexpression also leads to nuclear condensation in neurons. These data show that phosphorylation of RasGRF1 by Cdk5 tightly regulates its levels, which is essential for proper cellular organization.


Subject(s)
Cell Nucleus/metabolism , Cyclin-Dependent Kinase 5/metabolism , Neurons/metabolism , ras-GRF1/metabolism , Animals , Binding Sites/physiology , CHO Cells , COS Cells , Calpain/metabolism , Cell Death/genetics , Cell Nucleus/genetics , Cerebral Cortex/metabolism , Chlorocebus aethiops , Cricetinae , Cricetulus , Cyclin-Dependent Kinase 5/genetics , Down-Regulation/genetics , Female , Gene Expression Regulation/genetics , Mice , Mice, Knockout , Neurons/cytology , Phosphorylation , Rats , Serine/metabolism , Signal Transduction/genetics , Up-Regulation/physiology , ras-GRF1/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...